Pancreatic Cancer Research

ResearcherYale Cancer CenterActive in the last 2 years

Stacey Stein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8970-9144; OpenAlex author ID A5012787104. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 8

  1. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. Co-author DOI 10.1001/jamaoncol.2024.1575↗
  2. Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Co-author DOI 10.21037/jgo-21-202↗
  3. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Bor… Co-author DOI 10.1097/mpa.0000000000001592↗
  4. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. First author DOI 10.21037/jgo.2018.03.07↗
  5. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. First author DOI 10.21037/jgo.2018.04.03↗
  6. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.45↗
  7. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Co-author DOI 10.1186/s40164-015-0025-y↗
  8. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Co-author DOI 10.1007/s12032-012-0361-2↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jill Lacy · 7 shared papers, 2013–2024 · strength 0.64
  2. Kimberly L. Johung · 5 shared papers, 2018–2024 · strength 0.59
  3. Michael Cecchini · 3 shared papers, 2020–2024 · strength 0.39
  4. Ronald R. Salem · 3 shared papers, 2016–2024 · strength 0.30
  5. Adriana Blakaj · 2 shared papers, 2018–2020 · strength 0.23
  6. Charles H. Cha · 2 shared papers, 2016–2024 · strength 0.19
  7. Howard S. Höchster · 3 shared papers, 2013–2016 · strength 0.16
  8. Timil H. Patel · 1 shared paper, 2021 · strength 0.14
  9. John W. Kunstman · 1 shared paper, 2024 · strength 0.14
  10. Guoping Cai · 1 shared paper, 2024 · strength 0.14
  11. Luisa F. Escobar‐Hoyos · 1 shared paper, 2024 · strength 0.14
  12. Mandar Deepak Muzumdar · 1 shared paper, 2024 · strength 0.14
  13. Adham Adel Jurdi · 1 shared paper, 2024 · strength 0.14
  14. Kenneth Reed Shroyer · 1 shared paper, 2024 · strength 0.14
  15. Bryan William Chang · 2 shared papers, 2016–2018 · strength 0.14
  16. Jay K. Pahade · 1 shared paper, 2020 · strength 0.11
  17. Charles E. Rutter · 1 shared paper, 2018 · strength 0.09
  18. Shane A. J. Lloyd · 1 shared paper, 2018 · strength 0.09
  19. Brandon R. Mancini · 1 shared paper, 2018 · strength 0.09
  20. Yue Zhang · 1 shared paper, 2015 · strength 0.07
  21. Krishna Soujanya Gunturu · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.